Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

Commitments and Contingencies - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013
University of Florida Research Foundation Licenses [Member]
License Agreement [Line Items]
License Agreement, Original Date	Jun. 22, 2000
Company's obligation to pay from percentage of selling price of product	5.00%
Company's obligation to pay from all revenue received from sublicenses	22.00%
One-time commercialization fee would be due on the first anniversary of first commercial sale	$ 5,000
Post-commercialization minimum royalty payments	50,000
One-time additional royalty payment would be due when total cumulative royalties	2,000,000
Total royalties due to UFRF	10.00%
Minimum annual maintenance payment per license agreement	10,000
Aggregate minimum annual maintenance payment	20,000
Quarterly maintenance payment to UFRF under installment plan	$ 5,000
Channel Collaboration Agreement [Member]
License Agreement [Line Items]
License Agreement, Original Date	Jun. 05, 2012
Percentage company pay on quarterly basis out of gross profit	25.00%
Company's obligation to make payment from all revenue received from sublicensing	50.00%
Period during which company cannot terminate license agreement voluntarily	18 months
Period during which company cannot terminate license agreement	12 months
Termination notice period	90 days
Number of shares issued	4,392,425
Maximum percentage of primary investment securities to investment of shares issued	10.00%
Channel Collaboration Agreement [Member] \| Clinical Study Phase 2 [Member]
License Agreement [Line Items]
Percentage of number of shares of common stock equal to Base Shares	1.50%
Channel Collaboration Agreement [Member] \| Clinical Study Phase 3 [Member]
License Agreement [Line Items]
Percentage of number of shares of common stock equal to Base Shares	2.00%
Channel Collaboration Agreement [Member] \| Filing of First Investigational New Drug Application [Member]
License Agreement [Line Items]
Percentage of number of shares of common stock equal to Base Shares	2.50%
Channel Collaboration Agreement [Member] \| First Regulatory Approval of Oragenics Product [Member]
License Agreement [Line Items]
Percentage of number of shares of common stock equal to Base Shares	3.00%
Channel Collaboration Agreement [Member] \| Investigational New Drug Application [Member]
License Agreement [Line Items]
Percentage of number of shares of common stock equal to Base Shares	1.00%
MU1140 [Member]
License Agreement [Line Items]
License Agreement, First Amendment Date	Sep. 15, 2000
License Agreement, Second Amendment Date	Jul. 10, 2002
License Agreement, Third Amendment Date	Sep. 25, 2002
License Agreement, Fourth Amendment Date	Mar. 17, 2003
License Agreement Date Fifth Amended	Apr. 19, 2013
Patents license expiration period	2017 through 2019
Smart Replacement Therapy [Member]
License Agreement [Line Items]
License Agreement, Original Date	Aug. 04, 1998
License Agreement, First Amendment Date	Sep. 15, 2000
License Agreement, Second Amendment Date	Jul. 10, 2002
License Agreement, Third Amendment Date	Sep. 25, 2002
License Agreement, Fourth Amendment Date	Mar. 17, 2003
License Agreement Date Fifth Amended	Apr. 19, 2013
Patent right filling date	Jun. 07, 1995
Patent effective date	Mar. 04, 1997
Patent Right Expire Date	Jun. 07, 2015